Halaven 0.44 mg (2ml) is an anti-cancer drug formulated under license by NerPharma, marketed by Eisai Pharmaceuticals. The generic name of this drug is Eribulin Mesylate. Halaven 0.44 mg (2ml) is approved by the US FDA and is widely used for the treatment of patients having metastatic breast cancer. It is available in the form of powder. We are one of the trusted Suppliers and Exporters of Halaven 0.44 mg (2ml) from Maharashtra, India.
Side Effects :
The most common side effects reported in ≥25% of patients receiving Halaven (eribulin mesylate) were low white blood cells; low red blood cells; weakness/tiredness; hair loss; numbness, tingling, or burning in the hands and feet; nausea; and constipation
The most common serious side effects reported in patients receiving Halaven (Eribulin Mesylate) were neutropenia with or without a fever.